Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FBS0701 dose-ranging study in chronic transfusional iron overload
ISRCTN17052121Phase 2Completed
- Sponsor
- FerroKin BioSciences
- Start
- Sep 2010
- Modality
- Small Molecules
01
Overview
Phase 2, open-label trial of deferitazole in transfusional hemosiderosis (2 arms), sponsored by FerroKin BioSciences. Primary endpoints: Safety and tolerability of two doses of FBS0701 and Differential response in liver iron content. Started Sep 2010; status: completed.
02
Drugs
deferitazole
03
Conditions
transfusional hemosiderosis
Beyond the preview
Go deeper on ISRCTN17052121.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN17052121.